Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 243

Similar articles for PubMed (Select 24299497)

2.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
3.

Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.

Montero-Odasso M, Wells JL, Borrie MJ, Speechley M.

BMC Neurol. 2009 Aug 12;9:42. doi: 10.1186/1471-2377-9-42.

4.

Rivastigmine: in Parkinson's disease dementia.

Siddiqui MA, Wagstaff AJ.

CNS Drugs. 2006;20(9):739-47; discussion 748-50. Review.

PMID:
16953649
5.

Exercise therapy for prevention of falls in people with Parkinson's disease: a protocol for a randomised controlled trial and economic evaluation.

Canning CG, Sherrington C, Lord SR, Fung VS, Close JC, Latt MD, Howard K, Allen NE, O'Rourke SD, Murray SM.

BMC Neurol. 2009 Jan 22;9:4. doi: 10.1186/1471-2377-9-4.

6.

Cholinesterase inhibitors for Parkinson's disease dementia.

Maidment I, Fox C, Boustani M.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004747. Review.

PMID:
16437494
7.

Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.

Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P, Witjas T, Delliaux M, Destée A, Duhamel A, Bordet R, Defebvre L, Dujardin K.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74. doi: 10.1136/jnnp-2013-306439. Epub 2013 Nov 11.

PMID:
24218528
8.

Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.

Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D; Parkgait-II study group.

Lancet Neurol. 2012 Jul;11(7):589-96. doi: 10.1016/S1474-4422(12)70106-0. Epub 2012 Jun 1. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22658702
9.

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R; EXPRESS Investigators.

Mov Disord. 2006 Apr;21(4):456-61.

PMID:
16229010
10.

Rivastigmine for dementia associated with Parkinson's disease.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.

N Engl J Med. 2004 Dec 9;351(24):2509-18.

11.

Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial.

Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, Chavret F, Hetherington V, Baker K, Lim I.

J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):134-40. Erratum in: J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1414. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):126.

12.
13.

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R.

Lancet Neurol. 2007 Jun;6(6):501-12. Erratum in: Lancet Neurol. 2007 Oct;6(10):849.

PMID:
17509485
14.

Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.

Wesnes K.

Drugs Today (Barc). 2007 Jun;43(6):349-59. Review.

PMID:
17612707
15.

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R.

Mov Disord. 2006 Nov;21(11):1899-907.

PMID:
16960863
16.
17.

Rivastigmine for vascular cognitive impairment.

Birks J, McGuinness B, Craig D.

Cochrane Database Syst Rev. 2013 May 31;5:CD004744. doi: 10.1002/14651858.CD004744.pub3. Review.

PMID:
23728651
18.

Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.

Weintraub D, Somogyi M, Meng X.

Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):443-9. doi: 10.1177/1533317511424892. Epub 2011 Oct 18.

PMID:
22009228
19.

Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.

Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann W, Tracik F.

Mult Scler. 2013 Apr;19(5):631-8. doi: 10.1177/1352458512463481. Epub 2012 Oct 15.

PMID:
23069874
20.

V-TIME: a treadmill training program augmented by virtual reality to decrease fall risk in older adults: study design of a randomized controlled trial.

Mirelman A, Rochester L, Reelick M, Nieuwhof F, Pelosin E, Abbruzzese G, Dockx K, Nieuwboer A, Hausdorff JM.

BMC Neurol. 2013 Feb 6;13:15. doi: 10.1186/1471-2377-13-15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk